Early Meetings Aid First-Cycle Approval If Sponsors Act, Consultants Tell FDA
This article was originally published in Pharmaceutical Approvals Monthly
NDA and BLA sponsors contribute to the need for multi-cycle reviews by failing to act on FDA recommendations made during development "milestone" meetings, according to an independent analysis of the agency’s first-cycle review performance.
You may also be interested in...
Sponsors of the most innovative new drugs should not be deterred by the apparent reversals of fortune in the last year for NDAs with priority review status, the consulting firm Parexel concludes in a new report.
FDA’s efforts to increase first-cycle approvals appear to be paying off, with the agency showing a significant improvement in 2003 compared to 2002.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011